Journal of Asthma
Volume 59, 2022 - Issue 1
Biologics
Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore
Ling Eng Tana Ministry of Health, Agency for Care Effectiveness, Singapore, Singapore
https://orcid.org/0000-0001-8140-6210
, MSchttps://orcid.org/0000-0001-8140-6210, Wan Hui Gloria Tana Ministry of Health, Agency for Care Effectiveness, Singapore, Singaporehttps://orcid.org/0000-0001-5168-536X
, MPHhttps://orcid.org/0000-0001-5168-536X, Mohamed Ismail Abdul Aziza Ministry of Health, Agency for Care Effectiveness, Singapore, Singaporehttps://orcid.org/0000-0003-3606-7672
, MSchttps://orcid.org/0000-0003-3606-7672, Mariko Siyue Kohb Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore;c Office of Clinical, Academic and Faculty Affairs, Duke NUS Medical School, Singapore, Singaporehttps://orcid.org/0000-0002-1230-0129
, MBBS, MRCPhttps://orcid.org/0000-0002-1230-0129, Tunn Ren Tayd Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore, Singaporehttps://orcid.org/0000-0001-5729-647X
, MBBS, MRCP, FAMShttps://orcid.org/0000-0001-5729-647X, , MPH & Kwong Nga Ministry of Health, Agency for Care Effectiveness, Singapore, SingaporeCorrespondence[email protected]
https://orcid.org/0000-0002-6511-1639
, MClinPharm, MPHhttps://orcid.org/0000-0002-6511-1639 show all